Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue.
Phase of Trial: Phase II/III
Latest Information Update: 05 May 2017
At a glance
- Drugs PG 2 (Primary)
- Indications Fatigue
- Focus Therapeutic Use
- Sponsors PhytoHealth
- 07 Jun 2017 Biomarkers information updated
- 03 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 05 Jun 2009 Planned end date changed from 1 Aug 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.